In Competitive RSV Market, GSK Aims To Be First For Adults 50-59

Results from a Phase III trial testing the RSV vaccine Arexvy in adults 50-59 met the two primary endpoints, potentially opening the door to a wider adult market.

building blocks
GSK is hoping to build out the label for its RSV vaccine • Source: Shutterstock

GSK plc stands to be the first to submit Phase III data to regulators for use of a respiratory syncytial virus (RSV) vaccine in adults 50-59, potentially broadening the adult market opportunity for the vaccine. Arexvy received US Food and Drug Administration approval in May for adults 60 and older almost simultaneously with Pfizer Inc.’s RSV vaccine Abrysvo. The vaccines are the first to reach the market for RSV lower respiratory tract disease, putting the two companies in a competitive commercial showdown.

Key Takeaways

  • GSK’s Phase III data on Arexy showed non-inferior immune responses in adults 50-59 at increased risk for RSV due to certain medical conditions.

GSK announced positive preliminary results from its Phase III trial on 25 October, showing non-inferior immune responses observed in adults...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Bavarian Nordic Well Placed To Meet Mpox Vaccine Demand

 

The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.  

Cagrisema Leads The Charge For 2025

 

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

More from Therapeutic Category

Scrip Data Article Without An Author

"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.